Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet

Corvus Pharmaceuticals (CRVS) closed the last trading session at $23.01, gaining 208.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28.83 indicates a 25.3% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $7.6. While the lowest estimate of $20.00 indicates a 13.1% decline from the current price level, the most optimistic an ...